Genomics Market By Product Type (Consumables, Instruments, Software & Services), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarrays, CRISPR Technology, Mass Spectrometry), By Application (Disease Diagnostics, Drug Discovery & Development, Personalized Medicine, Agricultural Genomics, Forensic Applications), By End-User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Healthcare Providers, Agriculture & Environmental Research, Government Agencies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Genomics Market was valued at USD 26.3 billion in 2024-e and will surpass USD 89.4 billion by 2030; growing at a CAGR of 19.1% during 2025 - 2030.

The genomics market has witnessed exponential growth over the past few years, driven by advancements in technology and an increasing demand for precision medicine and personalized treatments. Genomics, which involves the study of genes and their functions, plays a crucial role in various fields such as healthcare, agriculture, and biotechnology. With the development of cutting-edge technologies, such as next-generation sequencing (NGS) and CRISPR, genomics is poised to revolutionize how diseases are diagnosed and treated. Additionally, genomic research is essential for understanding the genetic basis of diseases, discovering new drug therapies, and improving agricultural yields.

Consumables Segment is Largest Owing to High Demand for Reagents and Kits

In the genomics market, consumables have emerged as the largest subsegment, largely due to the high demand for reagents, kits, and other consumables used in genomic research. Reagents and kits are integral for the preparation of DNA and RNA samples, enabling accurate and efficient genomic analysis. Their widespread use in both research and clinical applications is driving the growth of this segment. With the increasing use of genomic tools for disease diagnostics, personalized medicine, and drug discovery, consumables are critical for supporting these applications. As the adoption of genomics in healthcare and research accelerates, the demand for consumables is expected to continue rising.

Next-Generation Sequencing (NGS) is Fastest Growing Technology Due to Precision and Efficiency

Among the various technologies in the genomics market, next-generation sequencing (NGS) is experiencing the fastest growth. NGS allows for the rapid sequencing of DNA and RNA, enabling researchers to decode genetic material quickly and accurately. The technology’s ability to produce large volumes of high-quality data in a short time has made it an invaluable tool for genomic research and diagnostics. It is particularly instrumental in personalized medicine, where genomic data is used to tailor treatments to individual patients. As the technology becomes more affordable and accessible, NGS is expected to play a pivotal role in advancing genomics research and clinical applications.

Disease Diagnostics Application is Largest Due to Widespread Adoption in Healthcare

Among the various applications of genomics, disease diagnostics stands as the largest, owing to its widespread adoption in healthcare settings. Genomic testing is increasingly being used to diagnose genetic disorders, identify cancer mutations, and detect infectious diseases. With the growing emphasis on early detection and personalized treatment plans, the demand for genomic diagnostics has surged. Advances in genomic testing technologies, such as PCR and NGS, have enabled faster, more accurate diagnoses, particularly in oncology and rare genetic diseases. As healthcare providers continue to embrace genomics for precision diagnostics, this application segment is expected to remain the dominant driver of market growth.

Pharmaceutical & Biotechnology Companies Drive Market Growth in End-User Industry

In the genomics market’s end-user industry, pharmaceutical and biotechnology companies are the largest segment. These companies rely heavily on genomics to discover new drugs, develop gene therapies, and enhance the effectiveness of existing medications. With the increasing focus on personalized medicine, pharmaceutical companies are leveraging genomic data to better understand patient responses to treatments and to create targeted therapies. Additionally, biotechnology firms are using genomic technologies such as CRISPR for gene editing and therapeutic development. As the pharmaceutical and biotechnology sectors continue to embrace genomics in drug development, this segment is poised for sustained growth in the coming years.

Largest Region: North America Leads the Genomics Market

North America is the largest region in the genomics market, driven by the strong presence of leading genomic companies and substantial investments in research and development. The United States, in particular, is home to many key players in the genomics space, such as Illumina, Thermo Fisher Scientific, and Roche Diagnostics. Additionally, the region has well-established healthcare systems that are increasingly incorporating genomic technologies for disease diagnosis, drug development, and personalized medicine. The availability of advanced infrastructure, government funding for research, and a high adoption rate of genomic technologies contribute to North America's dominance in the global market. As genomic research continues to expand, North America is expected to maintain its position as the largest market for genomics.

Competitive Landscape and Leading Companies

The competitive landscape of the genomics market is highly dynamic, with numerous companies at the forefront of technological innovation and product development. Leading companies in the genomics market include Illumina Inc., Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, and Bio-Rad Laboratories. These companies are continuously advancing genomic technologies, developing new products, and expanding their portfolios to cater to the growing demand for genomic testing, research, and drug development.

Companies are also engaging in strategic partnerships, acquisitions, and collaborations to enhance their product offerings and market reach. For example, collaborations between pharmaceutical companies and genomics firms are becoming increasingly common, as they aim to integrate genomic data into drug discovery and clinical trials. As the genomics market continues to evolve, competition is expected to intensify, with both established players and new entrants striving to gain a competitive edge through technological innovation, product diversification, and strategic alliances.

Recent Developments:

• Illumina - Launched the NovaSeq 6000 system, offering enhanced sequencing capabilities for both research and clinical applications.
• Thermo Fisher Scientific - Acquired Mesa Biotech, expanding its molecular diagnostics portfolio, particularly in point-of-care testing.
• Roche - Partnered with Guardant Health to develop a blood-based test for detecting cancer-related genomic alterations.
• QIAGEN - Announced a new collaboration with Gilead Sciences to develop diagnostic solutions using next-gen sequencing technology.
• Oxford Nanopore Technologies - Received FDA clearance for its Flongle platform, a portable DNA sequencing device for rapid diagnostic applications

List of Leading Companies:

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Agilent Technologies
• Pacific Biosciences of California, Inc.
• Bio-Rad Laboratories
• PerkinElmer, Inc.
• QIAGEN N.V.
• BGI Group
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies
• Danaher Corporation
• 23andMe Inc.
• Invitae Corporation
• Guardant Health

Report Scope: